The Global Long Acting Drug Delivery Market was valued at USD 1,536 Million in 2023 and is projected to reach USD 2,573.09 Million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 5.90% during the forecast period (2023-2032). This growth is being driven by increasing prevalence of chronic diseases, rising demand for patient-friendly treatment options, and significant investments in advanced drug delivery technologies.
As the pharmaceutical industry shifts toward personalized medicine and improved treatment adherence, long acting drug delivery systems are becoming indispensable for maintaining therapeutic efficacy. These technologies enable sustained drug release over extended periods, offering clinical benefits for chronic conditions. In this analysis, we examine the Top 10 Companies in the Long Acting Drug Delivery Market—innovators developing cutting-edge formulations, implantable devices, and biologics delivery solutions.
🔟 1. ViiV Healthcare
Headquarters: Brentford, United Kingdom
Key Offering: Long-acting injectable HIV therapies
ViiV Healthcare, a global specialist HIV company majority-owned by GSK, leads in long-acting injectable antiretroviral therapies. Their Cabenuva (cabotegravir + rilpivirine) represents the first complete long-acting regimen for HIV maintenance therapy.
Innovation Highlights:
- Monthly/2-monthly injection regimens replacing daily oral therapy
- Proprietary nano-suspension technology
- Pipeline includes ultra-long-acting formulations (6+ month duration)
Download FREE Sample Report: Long Acting Drug Delivery Market – View in Detailed Research Report
9️⃣ 2. Halozyme Therapeutics
Headquarters: San Diego, California, USA
Key Offering: ENHANZE drug delivery technology
Halozyme’s proprietary ENHANZE platform enables subcutaneous delivery of biologics that traditionally required intravenous administration, transforming treatment experiences for patients with chronic conditions.
Innovation Highlights:
- Recombinant human hyaluronidase PH20 technology
- Approved in 8+ partnered products globally
- Reduces infusion time from hours to minutes
8️⃣ 3. Lubrizol Life Science
Headquarters: Wickliffe, Ohio, USA
Key Offering: Advanced polymer drug delivery systems
Lubrizol provides critical material solutions for long-acting drug delivery, including biodegradable polymer technologies for implants and injectable depots with controlled release profiles.
Innovation Highlights:
- Pellethane™ and TECOFLEX™ medical-grade polymers
- Customizable release kinetics from weeks to years
- GMP manufacturing capabilities
Download FREE Sample Report: Long Acting Drug Delivery Market – View in Detailed Research Report
7️⃣ 4. Celanese Corporation
Headquarters: Irving, Texas, USA
Key Offering: VitalDose™ sustained-release technologies
Celanese’s drug delivery solutions enable precise control over release kinetics through innovative polymer matrices, with applications across small molecules and biologics.
Innovation Highlights:
- Bioerodible polymer platforms
- Drug-polymer compatibility expertise
- Regulatory and scale-up support
6️⃣ 5. Kashiv BioSciences
Headquarters: Bridgewater, New Jersey, USA
Key Offering: Advanced drug delivery platforms
Kashiv BioSciences develops proprietary technologies for sustained drug release, including microsphere and implant-based delivery systems for specialty pharmaceuticals.
Innovation Highlights:
- ProLease™ microsphere technology
- ReForm™ implant technology
- Biologics stabilization expertise
5️⃣ 6. 4P Therapeutics
Headquarters: Saint Paul, Minnesota, USA
Key Offering: Targeted long-acting delivery systems
4P Therapeutics specializes in precision drug delivery solutions providing localized, sustained release for neurological, ophthalmic, and oncological applications.
Innovation Highlights:
- Site-specific therapeutic approaches
- Combination product development
- Novel formulation technologies
4️⃣ 7. Ipsen
Headquarters: Paris, France
Key Offering: Peptide-based long-acting formulations
Ipsen has pioneered extended-release peptide therapeutics, particularly in neuroendocrinology and oncology, with depot formulations providing months of therapeutic effect.
Innovation Highlights:
- 1-3 month somatostatin analog formulations
- Established manufacturing infrastructure
- Biologics pipeline expansion
Read Full Report: Long Acting Drug Delivery Market – View in Detailed Research Report
3️⃣ 8. Midatech Pharma
Headquarters: Abingdon, United Kingdom
Key Offering: Q-Sphera™ microsphere technology
Midatech’s patented Q-Sphera platform produces uniform, long-acting microspheres with precise release profiles using innovative manufacturing processes.
Innovation Highlights:
- Microfluidic-based production
- Tunable release profiles (weeks to months)
- CNS and oncology applications
2️⃣ 9. Re-Vana Therapeutics
Headquarters: Belfast, United Kingdom
Key Offering: OcuMedic™ ocular implant technology
Re-Vana develops biodegradable ocular implants capable of delivering therapeutic agents for up to two years from a single administration.
Innovation Highlights:
- Multi-year drug delivery solutions
- Chronic retinal disease focus
- Scalable manufacturing processes
1️⃣ 10. Creative Biolabs
Headquarters: Shirley, New York, USA
Key Offering: Custom formulation development services
Creative Biolabs provides comprehensive services for sustained-release formulation development, from feasibility studies to GMP manufacturing support.
Innovation Highlights:
- Protein/antibody stabilization
- Advanced characterization
- Multi-month release formulations
Read Full Report: Long Acting Drug Delivery Market – View in Detailed Research Report
🌍 Outlook: The Future of Long Acting Drug Delivery
The long acting drug delivery market is undergoing rapid transformation as developers address the growing need for improved treatment adherence and patient convenience. With chronic disease prevalence rising globally, extended-release technologies are becoming essential components of therapeutic regimens.
📈 Key Trends Shaping the Market:
- Biologics formulation advancements enabling long-acting protein therapies
- Novel polymer technologies allowing multi-month release profiles
- Shift toward subcutaneous alternatives to IV administration
- Regulatory support for patient-centric drug development
- Combination product innovation (device + drug)
The companies profiled above represent the forefront of pharmaceutical delivery innovation—transforming treatment paradigms through science that maintains therapeutic effectiveness while improving patient quality of life.